Criteria of effective infliximab therapy of RF-positive patients with rheumatoid arthritis
At present, there are a few biologic agents (etanercept, tocilizumab, rhituximab, adalimumab) which uses in the treatment of rheumatoid arthritis. The problem is difficulties with the selection of necessary drug. Wide spreading of usage of anti-TNF-а drugs is observed, however main criteria of effective treatment, duration of infliximab’s courses are still unknown. For the first time in present study status of immune system and cytokine profile of RF-positive patients during infliximab treatment was observed. Algorithm of prognosis effective infliximab therapy has been developed which include monitoringof status of immune system and concentration of key inflammatory cytokines: TNF-а, IL-6, IL-lß, IL-17 in serum and supernatants of PMBC. Positive dynamic of these markers is the evidence of effective infliximab therapy.